» Articles » PMID: 12883040

Gene Expression Profiles in a Panel of Childhood Leukemia Cell Lines Mirror Critical Features of the Disease

Overview
Journal Mol Cancer Ther
Date 2003 Jul 29
PMID 12883040
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The development of new drugs against cancer requires established cell lines. They are needed for in vitro studies to identify candidate drugs and in xenograft models to measure drug efficacy in vivo. Specific criteria need to be fulfilled by cell lines used in the evaluation of potential novel therapeutic agents. It is imperative that they display the features of the particular cancer under investigation. Given the documented heterogeneity of cancers, relevant subtypes need to be represented. In this study, we have examined these aspects for pediatric acute lymphoblastic leukemia. A panel of 13 leukemia cell lines recently established in our laboratory was analyzed. We used cDNA microarrays to define the gene expression profiles and compared the data with immunophenotyping and cytogenetic analyses. The expression profiles obtained showed excellent concordance with corresponding protein levels. Importantly, the panel of lines displayed the critical genetic features identified in clinically important acute lymphoblastic leukemia subtypes in childhood leukemia patients.

Citing Articles

Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.

Karsa M, Kosciolek A, Bongers A, Mariana A, Failes T, Gifford A Br J Cancer. 2021; 125(1):55-64.

PMID: 33837299 PMC: 8257682. DOI: 10.1038/s41416-021-01332-x.


Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.

Fahy L, Calvo J, Chabi S, Renou L, Le Maout C, Poglio S Blood Adv. 2021; 5(2):513-526.

PMID: 33496749 PMC: 7839374. DOI: 10.1182/bloodadvances.2020002832.


Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia.

Foley B, Ta C, Barnes S, de Jong E, Nguyen M, Cheung L Clin Transl Immunology. 2020; 9(7):e1151.

PMID: 32695339 PMC: 7365579. DOI: 10.1002/cti2.1151.


Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.

Somers K, Evans K, Cheung L, Karsa M, Pritchard T, Kosciolek A Leukemia. 2019; 34(6):1524-1539.

PMID: 31848452 PMC: 9110273. DOI: 10.1038/s41375-019-0683-6.


A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.

Somers K, Wen V, Middlemiss S, Osborne B, Forgham H, Jung M Oncogene. 2019; 38(20):3824-3842.

PMID: 30670779 PMC: 6756102. DOI: 10.1038/s41388-018-0666-5.